Which of the following inhalational anesthetic agent is contraindicated in liver disease?
**Core Concept**
Halothane is a potent inhalational anesthetic agent that has been associated with severe liver injury, known as halothane hepatitis. This condition is thought to be due to an immune-mediated response to liver cells that have been altered by the metabolism of halothane. The exact mechanism is not fully understood, but it is believed to involve the formation of reactive metabolites that trigger an immune response.
**Why the Correct Answer is Right**
Halothane is metabolized by the liver enzyme cytochrome P450, which can lead to the formation of toxic metabolites that damage liver cells. In susceptible individuals, this can trigger a severe immune response, resulting in liver failure. Halothane has been shown to cause liver injury in both animals and humans, and it is considered a contraindication in patients with liver disease. The risk of halothane hepatitis is higher in patients with pre-existing liver damage, making it a critical consideration in patients with liver disease.
**Why Each Wrong Option is Incorrect**
**Option A:** Methoxyflurane is also metabolized by the liver, but it is not associated with the same level of liver toxicity as halothane. In fact, methoxyflurane is often used in patients with renal disease due to its ability to cause a high degree of renal vasodilation.
**Option C:** Ether, or diethyl ether, is an older inhalational anesthetic agent that is no longer commonly used. While it does have some hepatotoxic effects, it is not as strongly associated with liver injury as halothane.
**Option D:** Isoflurane is a modern inhalational anesthetic agent that is considered to have a low risk of liver toxicity. It is often used in patients with liver disease due to its ability to cause minimal changes in liver function.
**Clinical Pearl / High-Yield Fact**
It's essential to note that the risk of halothane hepatitis is higher in patients who have received multiple exposures to the agent, particularly in the absence of a washout period. This highlights the importance of careful patient selection and monitoring when using halothane in clinical practice.
**β Correct Answer: B. Halothane**